First Round News Hubb
Advertisement Banner
  • Home
  • First Round News
  • Funding News
  • Contact
No Result
View All Result
  • Home
  • First Round News
  • Funding News
  • Contact
No Result
View All Result
First Round News Hubb
No Result
View All Result
Home Funding News

iOnctura gets €17.5M funding to develop novel pancreatic cancer therapy

admin by admin
December 30, 2022
in Funding News



The Netherlands-based iOnctura BV, a clinical-stage biotech developing novel cancer therapies, recently that it has been granted €17.5 million funding from the European Investment Council’s (EIC) Accelerator Program. With the latest funding they will work on the advancement of their product – IOA-289 (a highly-selective, first-in-class autotaxin inhibitor, to transform the treatment of pancreatic cancer).

The EIC’s funding consists of a grant of €2.5 million, and €15 million of equity investment. Recently, Onctura also announced the first patient was dosed in a Phase Ib clinical trial of IOA289 in metastatic pancreatic cancer.

Catherine Pickering, Chief Executive Officer of iOnctura, said: “We are delighted to announce this funding from the EIC to support the clinical development of IOA-289 for the treatment of pancreatic cancer. Pancreatic cancer is the only cancer with mortality on the rise in both sexes and is currently the 3 rd largest cause of death by cancer in the US, and the 4 th in Europe.

“There’s an urgent need to develop new therapies for pancreatic cancer and preclinical data demonstrate that IOA-289 offers a new approach, through a multi-pronged mechanism that addresses three hallmarks of cancer: fibrosis, immune suppression and tumor cell proliferation.”

The funding came as part of the most recent tranche of grants from the EIC Accelerator program under Horizon Europe, that aims to accelerate deep tech startups through grants and equity investments.

For this second wave of grants, the European Commission selected 78 innovative startups for funding during a highly competitive process. In all, 240 companies were interviewed by juries of experienced investors and entrepreneurs out of a total of more than 1,000 applications. The selected companies will together receive up to €470 million of funding in a combination of grants and equity investments.

The post iOnctura gets €17.5M funding to develop novel pancreatic cancer therapy appeared first on Tech Funding News.



Source link

Previous Post

The Capital Quest | Naresh Patwari’s Jashvik Capital bets on snacks maker in maiden PE deal

Next Post

Gen Zers Talk of Their Keywords of 2022 and Their Vision for 2023

Next Post

Gen Zers Talk of Their Keywords of 2022 and Their Vision for 2023

Recommended

Cloudflare Named to Top 100 Most Loved Workplaces in 2022

2 months ago

French self-hypnosis app that helps people quit smoking, lose weight and sleep better gets $5.1M

5 days ago

How to Prepare for a New Era of Real

1 month ago

The Edit LDN, the ‘Farfetch of sneakers,’ straps $4.8M for its Metaverse store and more

3 weeks ago

Creative AI is accelerating, and so are the challenges

5 months ago

The Capital Quest | KKR adds to India investment spree with bet on seed company

3 months ago

first-round-white

© 2022 First Round News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • First Round News
  • Funding News
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • First Round News
  • Funding News
  • Contact

© 2022 First Round News Hubb All rights reserved.